Dialysis industry news

Stories from the dialysis comunity across the globe.



Is Covidien buying hypertension treatment firm Maya Medical? - MedCity News PDF Print

The intense competition for the best treatment of runaway hypertension looks like it’s about to heat up. Word is that Massachusetts-based Covidien, which has been on a buying spree, is going to acquire early stage California medical technology company Maya Medical.

Renal denervation is the potential solution for the 12 million people who can’t control their high blood pressure despite using an array of drugs. The treatment uses a catheter to widen the areas around the nerves that line renal arteries. The Cleveland Clinic called renal denervation the No. 1 healthcare innovation of 2012.

A Covidien spokesman wouldn’t comment on what he described as “market rumors and speculation,” but conceded that the company is in “partnership with Maya on a new technology.” The spokesman, Bruce Farmer, went on to add that Covidien makes strategic investments from time to time and “is a recognized market leader in RF ablation technology, with numerous products in both its vascular and surgical portfolios. …”

RF ablation is what Maya Medical’s solution is all about.

In about two weeks, Covidien is sponsoring a panel at the EuroPCR conference in Paris that will highlight Maya Medical’s OneShot technology. In a separate panel, Maya Medical’s s own chief medical officer, Michel Accad, will talk about OneShot as the “next generation balloon-based, radio frequency renal denervation system.”

A call to Maya Medical wasn’t immediately returned. The company is currently conducting a phase 2 clinical study in Belgium and The Netherlands, although the medical centers are not recruiting patients yet.

While Covidien is sponsoring Maya Medical’s OneShot panel, Medtronic and St. Jude Medical are sponsoring renal denervation panels that highlight technologies they actually own.

A source in the renal denervation industry with knowledge of the deal between Covidien and Maya Medical said that device firms do not sponsor panels unless they own the technology being discussed or have an interest in it.

Covidien’s interest in Maya Medical’s renal denervation technology is understandable. An analyst who covers Covidien said that early clinical data on renal denervation is very promising and that the market is large.

“It’s in the billions of dollars and there is a huge need,” said Michael Matson, an equity analyst with Mizuho Securities USA.

He added that Covidien typically buys companies in new growth platforms with acquisitions at around $500 million or less. The company has bought four companies in 2012 that fit this description. One exception is ev3, which Covidien bought for more than $2.5 billion in 2010.

The Maya Medical deal, if and when it happens, will bring Covidien into competition with Medtronic and St. Jude Medical. Medtronic is the leader in the renal denervation field with its prescient acquisition of Ardian for $800 million in late 2010. While the system works, it is hard to manipulate, said analyst Debbie Wang of Morningstar. She said that Medtronic will have to buy another renal denervation firm developing the next generation of these devices to remain ahead. Medtronic’s Simplicity renal denervation system is approved in Europe and the company is currently enrolling patients in a U.S. clinical trial that will be used for wining regulatory approval here.

St. Jude Medical is also developing a renal denervation system and expects to get the CE Mark by the end of the year.

And there are a whole host of small, private companies that are also developing solutions — ReCor Medical, SeptRX and Apex Nano Therapeutics, all of whom will be discussing their technologies at the upcoming EuroPCR conference in mid May. Vessix Vascular just received a CE mark for its renal denervation system.

[Image from flickr user BostonTX]

 

...

 
Patients with Diabetes Not at Highest Risk for Contrast-Induced Nephrotoxicity - Diagnostic Imaging PDF Print
Diagnostic Imaging
Instead, patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency, putting them at greater risk, according to their study, designed to find which group of patients at highest risk for ...
New study challenges current thinking on risk factors for contrast induced

...

 
Researchers determine vitamin D blood level for reducing major medical risks ... - EurekAlert (press release) PDF Print
[ Back to EurekAlert! ] Public release date: 1-May-2012
[ | E-mail | Share Share ]

Contact: Leila Gray
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
206-685-0381
University of Washington

Association of low blood concentrations with major disease events, like heart attacks, varies with seasons

In testing older patients' blood vitamin D levels, there's uncertainty about where the dividing line falls between enough and not enough. The threshold amount has become controversial as several scientific societies set different targets.

To help resolve this debate, University of Washington researchers conducted an observational study. They wanted to learn how much vitamin D must be circulating in the blood to lower the risk of a major medical event. This category included heart attack, hip fracture, diagnosis of cancer, or death.

Their findings are reported today, May 1, in the Annals of Internal Medicine. Dr. Ian de Boer, assistant professor of medicine in the Division of Nephrology and a member of the Kidney Research Institute, led the project. He also holds an appointment in the Department of Epidemiology, UW School of Public Health.

Vitamin D is measured in the blood as 25-hydroxy-vitamin D, abbreviated 25(OH)D.

The researchers tested 25(OH)D concentrations from a biorepository of blood samples of 1,621 Caucasian adults. These adults had enrolled in the early 1990s in the Cardiovascular Health Study, originally designed to look at risk factors and progression of heart disease in people age 65 and over. The participants lived in one of four areas in the United States: Forsyth County, North Carolina; Sacramento, County, California; Washington County, Maryland; and Philadelphia, Pennsylvania.

Over about an 11-year follow-up, researchers looked at the association between each individual's 25(OH)D test results and the time that a first defining medical event occurred. Among the participants, 1,018 had such an event. There were 137 hip fractures, 186 heart attacks (myocardial infarctions), 335 incidences of cancer, and 360 deaths.

Through their statistical analysis, the researchers concluded that the risk of these disease events rose when the concentration of 25(OH)D fell below 20 ng/milliliter or 50 nmol/liter.

"Our results," de Boer said, "lend support to the threshold level recently recommended by the Institute of Medicine, a national, independent government advisory group."

He added, "This target level for adults is considerably lower than that set by other expert panels.'

His research team also found that the association of low 25(OH)D blood concentrations with risk of major disease events varied with the season. Because people soak up most of their Vitamin D from the sun, their levels run highest in the summer and lowest in the winter. Levels in autumn are generally above those in spring.

"In evaluating health risk," the researchers concluded, "Season-specific targets for 25(OH)D blood concentration may be more appropriate than a static target when evaluating patients health risk."

Future research in this area, de Boer said, will require clinical trials. Researcher will look, for example, at the health effects of attempts to raise 25(OH)D in patients whose levels fall below the target. Interventions might include supplements, dietary changes and increasing outdoor activity.

"Sun exposure is tricky," de Boer said, "because people have to protect themselves from skin cancer and other sun damage." Sunscreen blocks the UVB waves responsible for producing Vitamin D. Food sources for Vitamin D are milk, fortified juice and cereal and oily fish like salmon, mackerel, cod and herring.

Vitamin D provides many different beneficial effects on health because it is actually not a vitamin, but a prohormone. It can suppress the hormonal systems that cause fluid to be retained and blood pressure to go up, modulate the function of immune cells, and stop abnormal cells from overgrowing.

In addition to de Boer, other UW authors of the research paper, "Serum 25-hydroxy vitamin D concentrations and risk of major clinical disease events in a community-based population" are Gregory Levin and Mary L. Biggs, Biostatistics; Cassianne Robinson-Cohen, Epidemiology; Andy Hoofnagle, Laboratory Medicine; David Siscovick, Cardiovascular Health Unit and Medicine and Epidemiology; and Bryan Kestenbaum, Nephrology, Kidney Research Institute and Epidemiology.

The research was funded by grants from the National Institutes of Health, including the National Heart, Lung and Blood Institute, the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, and the National Institute of Diabetes and Kidney Disease.



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


...

 
Renal Transplant Failure Linked To Elevated Pre-Transplant iPTH - Renal Business Today PDF Print

ST. JOHN'S, NEWFOUNDLAND—Renal transplant recipients who had elevated pre-transplant levels of intact parathyroid hormone (iPTH) are at increased risk of post-transplant hypercalcium and graft rejection, according to findings presented at the Canadian Society of Nephrology's 2012 annual meeting.

“The association of pre-transplant iPTH level with outcome is interesting and clearly suggests mineral metabolism is important in post-transplant outcome,” John Gill, MD said. “The mechanisms which underlie this association need further study.”

Gill, a transplant nephrologist at St. Paul's Hospital in Vancouver, B.C., and his co-investigators made this discovery when gathering information about the increasingly common phenomena of hyperparathyroidism and hypercalcemia in kidney transplant patients. The researchers reviewed information from 1,352 consecutive adults who received kidneys alone between January 2000 an August 2007 in two of Canada's largest transplant centers, St. Paul's Hospital and the Toronto General Hospital.

A “striking” 40 percent of the patients had at least one episode of hypercalcemia—defined as albumin-corrected serum calcium level of 2.6 mmol/L or greater—within a year of transplantation, according to the investigators. Furthermore, 162 patients (12%) had post-transplant hypercalcemia throughout the first post-transplant year. Hypercalcemia resolved within two years in 25 percent of patients with this condition, and it resolved within three and five years post-transplant in 36 percent and 54 percent, respectively, of the affected cohort. Twenty-one (13%) of hypercalcemic patients required surgical parathyroidectomy.

...

 
Nephroplus scouts for partnerships - Business Standard (blog) PDF Print

<![CDATA[ .adTitle {color:#0253b7;text-decoration:none; font-family: Arial; font-size:14px; font-weight: bold; font-style: normal;} .adText {text-decoration:none; font-family: Arial; font-size: 12px; font-weight: normal; font-style: normal;color: #000000} .adbtmlink{color:#0253b7;text-decoration:none; font-family: Arial; font-size:12px; font-weight: normal; font-style: normal;} .adsby{color:gray;text-decoration:none; font-family: Arial; font-size:10px; font-weight: normal; font-style: normal;} .adborder{border:1px solid #CCCCCC;} ]]>
' + google_ads[0].line1 + ' : ' + google_ads[0].line2 + ' ' + google_ads[0].line3 + '
' + google_ads[0].visible_url + '
'; } else if (google_ads.length > 1) { s += 'Ads by Google
' /* * For text ads, append each ad to the string. */ for(i = 0; i ' + google_ads[i].line1 + ' :' + google_ads[i].line2 + '' + google_ads[i].line3 + '
' + google_ads[i].visible_url + '
'; } } } if (google_ads[0].bidtype == "CPC") { /* insert this snippet for each ad call */ google_adnum = google_adnum + google_ads.length; } document.write(s); return; } /* custom_468x60_storypage, created 11/23/10 */ google_ad_client = 'pub-1723933259695999'; /* substitute your client_id (pub-#) */ google_ad_slot = '0944360174'; google_ad_output = 'js'; google_max_num_ads = '1'; google_ad_type = 'text_html'; google_image_size = '600x15'; google_feedback = 'on'; google_skip = google_adnum; /* to skip for multiple units, insert this snippet for each ad call */ // -->

Hyderabad-based kidney care and dialysis clinics start-up Nephroplus, backed by funding from Bessemer Venture Partners, is looking at partnering small and mid-sized hospitals to set up 70 kidney dialysis centres and clinics.

“As part our proposed plan to set up 100 centres across the country over the next three years, we are looking for partnerships with 100-300-bedded small and mid-sized hospitals to create around 70 clinics. The remaining 30 centres will be opened by the company,” said Vikram Vuppala, founder and chief executive of Nephroplus.

<![CDATA[ .rightDiv2{float:right;position:relative;width:220px;padding:1px} .leftDiv2{float:left;position:relative;width:140px} ]]>

Each clinic costs between Rs 80 lakh and Rs 2 crore, with a capacity to treat 70-80 patients at a time. Currently, Nephroplus has 10 clinics across south India.

The company also has plans to set up 40 centres in north India. “Expanding into northern regions is our current priority. To start with, we will be setting up clinics in Kanpur next week,” he said.

Nephroplus has joined hands with Brian JG Pereira, who served as the president of the National Kidney Foundation, and currently an adjunct professor of medicine at Tufts University School of Medicine. Pereira has joined the board as a director.

...

 
<< Start < Prev 741 742 743 744 745 746 747 748 749 750 Next > End >>

Page 747 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.